Tom Rolf

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

Rhea N. Coler, Tracey A. Day, Ruth D. Ellis et al. · npj Vaccines · 2018 · 164 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH‐F3+GLA‐SE

Rhea N. Coler, Malcolm S. Duthie, Kimberly A. Hofmeyer et al. · Clinical & Translational Immunology · 2015 · 157 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Tracey A. Day, Adam Penn‐Nicholson, Angelique Kany Kany Luabeya et al. · The Lancet Respiratory Medicine · 2020 · 103 citations

Veterinary Medicine, Immunology, Infectious Diseases +10

A structure‐function approach to optimizing TLR4 ligands for human vaccines

Darrick Carter, Christopher B. Fox, Tracey A. Day et al. · Clinical & Translational Immunology · 2016 · 54 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA–SE) in healthy adults

Malcolm S. Duthie, Aude Frevol, Tracey A. Day et al. · Vaccine · 2019 · 31 citations

Veterinary Medicine, Immunology, Infectious Diseases +13